Loading clinical trials...
Loading clinical trials...
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Conditions
Interventions
Placebo Cream
Ruxolitinib Phosphate Cream
Locations
18
United States
Birmingham, Alabama, United States
Hot Springs, Arkansas, United States
New Haven, Connecticut, United States
Trumbull, Connecticut, United States
Miami, Florida, United States
Beverly, Massachusetts, United States
Start Date
November 18, 2015
Primary Completion Date
October 3, 2017
Completion Date
October 3, 2017
Last Updated
December 16, 2020
NCT06826196
NCT06562270
NCT07133308
NCT06327581
NCT07023302
NCT07152119
Lead Sponsor
Incyte Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions